Corneal Findings Associated to Belantamab-Mafodotin (Belamaf) Use in a Series of Patients Examined Longitudinally by Means of Advanced Corneal Imaging

Ocular Toxicity of Belantamab Mafodotin, an Oncological Perspective of Management in Relapsed and Refractory Multiple Myeloma

(2021) Ahsan Wahab et al.   Frontiers in Oncology

Structural changes of corneal epithelium in belantamab-associated superficial keratopathy using anterior segment optical coherence tomography

(2021) Wataru Matsumiya et al.   American Journal of Ophthalmology Case Reports

Corneal in vivo confocal microscopy to detect belantamab mafodotin-induced ocular toxicity early and adjust the dose accordingly: a case report

(2021) Kevin Marquant et al.   Journal of Hematology & Oncology

The impact of anticancer drugs on the ocular surface

(2020) Jeremy Chung Bo Chiang et al.   Ocular Surface

Ocular Side Effects of EGFR-Inhibitor ABT-414 in Recurrent Glioblastoma: A Long-Term Safety Study

(2020) Raffaele Parrozzani et al.   Frontiers in Oncology

Clinical and Histological Characterization of Toxic Keratopathy From Depatuxizumab Mafodotin (ABT-414), an Antibody-Drug Conjugate

(2020) Brian A. Lee et al.   CORNEA

Corneal Changes After Belantamab Mafodotin in Multiple Myeloma Patients

(2020) Rebecca B. Bausell et al.   Eye & Contact Lens-Science and Clinical Practice

Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study

(2019) Suzanne Trudel et al.   Blood Cancer Journal

Ocular surface system alterations in ocular graft-versus-host disease: all the pieces of the complex puzzle

(2019) Giuseppe Giannaccare et al.   GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

(2019) Sagar Lonial et al.   LANCET ONCOLOGY